Key result
Aspirin use increased the risk of first-time non-variceal upper gastrointestinal bleeding compared to matched controls (HR 1.48; 95% CI 1.28-1.72).
Why the study?
Does aspirin use increase the risk of first-time non-variceal upper gastrointestinal bleeding in a general population cohort?
Cohort (n=22,210)
Does aspirin use increase the risk of first-time non-variceal upper gastrointestinal bleeding in a general population cohort?
Hazard Ratio: 1.48 (95% CI 1.28–1.72)
Aspirin use significantly increases the risk of first-time non-variceal upper gastrointestinal bleeding, with multiple clinical and pharmacological factors independently exacerbating this risk.
Supports gastroprotection consideration in aspirin users with comorbidities; leaves open whether risk-factor modification reduces UGIB in prospective trials.
BACKGROUND/PURPOSE: We aimed to identify the risk factors of first-time occurrence of non-variceal upper gastrointestinal bleeding (UGIB) among aspirin users after adjusting for confounding factors like age, gender, underlying co-morbidities, and medications. METHODS: Using the National Health Insurance Research Database of Taiwan and matching age, gender, underlying co-morbidities and enrollment time by propensity score, 11105 aspirin users and 11105 controls were identified for comparison from a cohort dataset of 1,000,000 randomly sampled subjects. Cox proportional hazard regression models were used to identify independent risk factors for first-time occurrence of non-variceal UGIB in the study cohort and in the aspirin users after adjusting for age, gender, underlying co-morbidities, and medications (e.g., non-steroidal anti-inflammatory drugs [NSAIDs], cyclooxygenase-2 [COX-2] inhibitors, steroids, thienopyridines, selective serotonin reuptake inhibitors, warfarin, and dipyridamole). RESULTS: By Cox proportional hazard regression analysis, aspirin use increased the risk of first-time occurrence of UGIB (hazard ratio [HR]: 1.48; 95% confidence interval [CI]: 1.28-1.72). Age, male gender, Helicobacter pylori (H. pylori)infection, diabetes, chronic kidney disease (CKD), cirrhosis, history of uncomplicated peptic ulcer disease (PUD), and use of NSAIDs, COX-2 inhibitors, steroids, and thienopyridines were independent risk factors for UGIB among aspirin users. CONCLUSION: In addition to age, male gender, H. pylori infection, and concomitant use of NSAIDs, COX-2 inhibitors, steroids, and thienopyridines, underlying co-morbidities including diabetes, CKD, cirrhosis, history of PUD are also important risk factors for first-time occurrence of non-variceal UGIB in aspirin users.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2018) conducted a cohort in Upper gastrointestinal bleeding (n=22,210). Aspirin vs. Non-users (controls) was evaluated on First-time occurrence of non-variceal upper gastrointestinal bleeding (UGIB) (HR 1.48, 95% CI 1.28-1.72). Aspirin use increased the risk of first-time non-variceal upper gastrointestinal bleeding compared to matched controls (HR 1.48; 95% CI 1.28-1.72).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: